Trials / Terminated
TerminatedNCT01766336
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 296 (actual)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Group 1 ELND005 | |
| DRUG | Group 2 ELND005 |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2013-01-11
- Last updated
- 2019-10-21
- Results posted
- 2016-05-13
Locations
46 sites across 4 countries: United States, Canada, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01766336. Inclusion in this directory is not an endorsement.